Current status and prospects of androgen depletion therapy for prostate cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 2, 2008, Pages 293-302

  Akaza, Hideyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

androgen depletion therapy; combined androgen blockade; endocrine therapy; guideline; maximal androgen blockade; primary androgen depletion therapy; prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FINASTERIDE; GONADORELIN AGONIST; HYDROCORTISONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CULTURAL FACTOR; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; ERECTILE DYSFUNCTION; HORMONE INHIBITION; HUMAN; LIBIDO DISORDER; MALE; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL RESEARCH; METASTASIS INHIBITION; MONOTHERAPY; ORCHIECTOMY; OVERALL SURVIVAL; PATIENT DECISION MAKING; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; WATCHFUL WAITING;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG THERAPY; FOLLOW-UP STUDIES; GUIDELINES AS TOPIC; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS;

EID: 42949158294     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.01.010     Document Type: Review

References (14)

1. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Science 97 (2006) 243-247
2. Japanese Urological Association. The prostate cancer treatment guideline 2006 (2006), KANEHARA & CO., LTD.
3. Mulrow C., Langhome P., and Grimshaw J. Integrating heterogeneous pieces of evidence in systematic reviews. Annals of Internal Medicine 127 (1997) 989-995
4. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. International Journal Urology 12 (2005) 46-61
5. Akaza H., Hinotsu S., Usami M., et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Japanese Journal of Clinical Oncology 34 (2004) 329-336
6. Cooperberg M.R., Grossfeld G.D., Lubeck D.F., et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. Journal of the National Cancer Institute 95 (2003) 981-989
7. Fleming C., Wasson J.H., Albertsen P.C., et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 269 (1993) 2650-2658
8. Miller D.C., Gruber S.B., Hollenbeck B.K., et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. Journal of the National Cancer Institute 98 (2006) 1134-1141
9. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology 25 (2007) 1596-1605 [Epub 2007 Apr 2]
10. Akaza H., Yamaguchi A., Matsuda T., et al. Superior anti-tumor efficacy of bicalutamide 80.mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Japanese Journal of Clinical Oncology 34 (2004) 20-28
11. Usami M., Akaza H., Arai Y., et al. Bicalutamide 80.mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multi-center trial in Japanese patients. Prostate Cancer and Prostatic Diseases 10 (2007) 194-201
12. Hinotsu S, Akaza H, Usami M, et al. Combined androgen blockade (CAB) with bicalutamide and a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in Japanese patients with advanced prostate cancer: long-term follow-up reporting overall and cause-specific survival. In: First European multidisciplinary meeting on Urological Cancers. 2007 [abstract 119].
13. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
14. Thompson I.M., Pauler Ankerst D., Coltman Jr. C.A., et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostae Cancer Prevention Trial. Journal of Clinical Oncology 25 (2007) 2999-3000